Journal of clinical medicine. 2025 Feb 25;14(5):1534. doi: 10.3390/jcm14051534 Q12.92025

Evaluation of Subclinical Left Ventricular Dysfunction in HIV Patients Receiving Abacavir, Dolutegravir, and Lamivudine Therapy with Novel Tissue Doppler Imaging Techniques

接受阿巴卡韦、多立韦瑞和拉米夫定治疗的HIV患者亚临床左心室功能障碍的新组织多普勒成像技术评估 翻译改进

作者单位 +展开

DOI: 10.3390/jcm14051534 PMID: 40095518

摘要 Ai翻译

Copyright © Journal of clinical medicine. 中文内容为AI机器翻译，仅供参考！

相关内容

• Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine

  奥比塔斯维-帕利他韦-利托那韦联合达萨布韦与治疗艾滋病的抗逆转录病毒药物多替拉韦或阿巴卡韦和拉米夫定之间相互作用的研究

  Amit Khatri et al.

  Antimicrobial agents and chemotherapy. 2016 Sep 23;60(10):6244-51.

• Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food

  多替拉韦、阿巴卡韦和拉米夫定复方制剂的生物等效性及其受食物影响的情况

  Stephen Weller et al.

  Journal of acquired immune deficiency syndromes (1999). 2014 Aug 1;66(4):393-8.

• Dolutegravir, abacavir and lamivudine as HIV therapy

  多替拉韦、阿巴卡韦和拉米夫定作为治疗艾滋病的药物

  Jose Vicente Fernandez-Montero et al.

  Expert opinion on pharmacotherapy. 2014 May;15(7):1051-7.

• Dolutegravir plus abacavir/lamivudine works in adolescents, but size matters

  多替拉韦搭配阿巴卡韦/拉米夫定对青少年有效，但疗效和体重有关

  Ferran Bossacoma Busquets et al.

  The Journal of antimicrobial chemotherapy. 2017 Oct 1;72(10):2958-2960.

• Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study

  一项开放性、多中心1/2期剂量确认研究：阿巴卡韦、多替拉韦和拉米夫定分散片和速释片在儿童艾滋病患者中的药代动力学、安全性及耐受性（IMPAACT 2019 研究）——第24周结果

  Kristina M Brooks et al.

  The lancet. HIV. 2023 Aug;10(8):e506-e517.

• Acute pancreatitis associated with dolutegravir and lamivudine/abacavir administration

  多替拉韦和拉米夫定/阿巴卡韦联合用药相关的急性胰腺炎

  Amelia B Thompson et al.

  AIDS (London, England). 2015 Jan 28;29(3):390-2.

• Dolutegravir / Abacavir / Lamivudine -- Benefit Assessment According to §35a Social Code Book V [Internet]

  多替拉韦/阿巴卡韦/拉米夫定---《第五卷社会法典》第35a节规定的效益评估[网络版]

  Institute for Quality and Efficiency in Health Care

  .

• Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study

  拉伏替尼/阿巴卡韦/拉米夫定与当前疗法在病毒抑制患者中的疗效比较（STRIIVING研究）：一项为期48周的随机、非劣效性、开放标签III期试验

  Benoît Trottier et al.

  Antiviral therapy. 2017;22(4):295-305.